Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04983368




Registration number
NCT04983368
Ethics application status
Date submitted
17/07/2021
Date registered
30/07/2021
Date last updated
8/04/2022

Titles & IDs
Public title
A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
Scientific title
XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem® in Healthy Elderly Volunteers
Secondary ID [1] 0 0
ACW0005
Universal Trial Number (UTN)
Trial acronym
XanaMIA-DR
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mild Cognitive Impairment 0 0
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Xanamem® 5 mg
Treatment: Drugs - Placebo
Treatment: Drugs - Xanamem® 10 mg

Experimental: Xanamem® 5 mg - Oral Xanamem® capsules 5 mg, to be administered once daily

Experimental: Xanamem® 10 mg - Oral Xanamem® capsules 10 mg, to be administered once daily

Placebo Comparator: Placebo - Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.


Treatment: Drugs: Xanamem® 5 mg
Oral Xanamem® ("UE2343") capsules 5 mg, administered orally once daily.

Treatment: Drugs: Placebo
Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.

Treatment: Drugs: Xanamem® 10 mg
Oral Xanamem® ("UE2343") capsules 10 mg, administered orally once daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Short-term efficacy: Assessment of changes of different doses of Xanamem® on cognition.
Timepoint [1] 0 0
Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up)
Primary outcome [2] 0 0
Assessment of safety and tolerability of different Xanamem® doses by the occurrence of Treatment-Emergent Adverse Events (TEAEs).
Timepoint [2] 0 0
10 Weeks [Baseline to Week 10 Follow-Up (4 Weeks Post Last Dose of Study Drug)]
Secondary outcome [1] 0 0
Short-term efficacy of different doses of Xanamem® on cognition
Timepoint [1] 0 0
Screening, Baseline, Week 2, Week 4, Week 6 (End of Treatment), Week 10 (Follow-Up)

Eligibility
Key inclusion criteria
1. Male or female aged 50 to 80

2. Body mass index 17.5 to < 35 kg/m2, inclusive at the time of screening

3. Mini-Mental State Score of = 25 points at screening

4. Must provide written informed consent
Minimum age
50 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Abnormalities in vital signs at screening or baseline

2. Clinically significant abnormal hematology or biochemistry values, as determined by
the investigator at screening and/or baseline.

3. Previous clinically significant systemic illness or infection within the past 4 weeks
prior to screening or baseline, as determined by the investigator

4. Clinically significant ECG abnormalities

5. Use of tobacco- or nicotine-containing products in the past month or unwillingness to
abstain during study participation

6. Participation in another clinical study of a drug or device

7. Known allergy to the study drug (Xanamem®) or any of the excipients

8. Subjects who are likely to be unable to comply with the study schedule and/ or
subjects with an inability to communicate well with the investigator

9. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen,
or hepatitis C antibodies at screening

10. Subjects with a history of drug abuse or addiction in the past 5 years.

11. Evidence of alcohol abuse (defined as greater than 21 standard units per week for
males and greater than 14 standard units per week for females)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/02/2022
Sample size
Target
Accrual to date
Final
107
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD
Recruitment hospital [1] 0 0
Paratus Clinical Research Canberra - Bruce
Recruitment hospital [2] 0 0
Paratus Clinical Research Western Sydney - Blacktown
Recruitment hospital [3] 0 0
Paratus Clinical Research Central Coast - Kanwal
Recruitment hospital [4] 0 0
Paratus Clinical Research Brisbane - Albion
Recruitment hospital [5] 0 0
USC Clinical Trials - Sippy Downs
Recruitment postcode(s) [1] 0 0
2617 - Bruce
Recruitment postcode(s) [2] 0 0
2148 - Blacktown
Recruitment postcode(s) [3] 0 0
2259 - Kanwal
Recruitment postcode(s) [4] 0 0
4010 - Albion
Recruitment postcode(s) [5] 0 0
4556 - Sippy Downs

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Actinogen Medical
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Avance Clinical Pty Ltd.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Xanamem® is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's
disease. This study drug has been designed to change the cortisol levels in the brain.
Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level
of cortisol will be a benefit in the treatment of Mild Cognitive Impairment in Alzheimer's
disease.

The purpose of this study in older volunteers is to investigate the smallest dose of Xanamem®
(5 mg or 10 mg) which works and to investigate which dose in this study will be used in the
upcoming clinical trials in patients.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04983368
Trial related presentations / publications
Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25.
Public notes

Contacts
Principal investigator
Name 0 0
Miriam Roesner
Address 0 0
Actinogen Medical Limited
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04983368